paclitaxel has been researched along with Neoplasms, Cystic, Mucinous, and Serous in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (6.67) | 29.6817 |
| 2010's | 37 (82.22) | 24.3611 |
| 2020's | 5 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Bixel, K; Brady, MF; Burger, RA; Casey, AC; Cosgrove, C; duPont, NC; Enserro, D; Fujiwara, K; Monk, BJ; Moxley, K; Rubin, S; Soper, J; Tewari, KS; Thaker, P; Wahner Hendrickson, AE; Walker, JL | 1 |
| Aghajanian, C; Bookman, MA; Chan, JK; Coleman, RL; Dinh, MH; Fleming, GF; Friedlander, M; Hashiba, H; Moore, KN; O'Malley, DM; Okamoto, A; Ratajczak, C; Steffensen, KD; Swisher, EM; Tewari, KS; Wu, M | 1 |
| Beesley, VL; Campbell, R; DeFazio, A; Friedlander, ML; Grant, P; King, MT; Nagle, CM; Obermair, A; Ross, TL; Webb, PM | 1 |
| Ishibashi, M; Nagase, S; Sakurada, S; Sato, I; Shigeta, S; Shimada, M; Tokunaga, H; Watanabe, Y; Yaegashi, N | 1 |
| Bast, RC; Jazaeri, A; Liu, J; Niu, N; Shen, W; Sood, AK; Zhong, Y | 1 |
| Bergzoll, C; Eva, L; Jamieson, A; Simcock, B; Sykes, P | 1 |
| Crim, A; Ding, K; Dvorak, J; Gillen, J; Greenwade, M; Gunderson, C; Moore, K; Rowland, M; Ruskin, R; Walter, A | 1 |
| Celebi, K; Kaban, A; Saip, P; Salihoglu, Y; Sozen, H; Topuz, S | 1 |
| Ancrile, BB; Birkholz, JH; Blandford, JT; Dye, CE; Gusani, NJ; Headlee, BD; Heisey, HD; Levenick, JM; Maranki, JL; Mathew, A; McGarrity, TJ; Moyer, MT; Sharzehi, S | 1 |
| Fuksiewicz, M; Gmyrek, L; Jonska-Gmyrek, J; Kotowicz, B; Kowalska, M; Kucharz, J; Michalski, W; Poniatowska, G; Wiechno, P; Zolciak-Siwinska, A | 1 |
| Barriuso, J; Berjón, A; Castelo, B; Crespo, R; Cruz, P; DE Molina, AR; Feliu, J; Hardisson, D; Heredia-Soto, V; Hernández, A; Herranz, J; Mendiola, M; Miguel-Martín, M; Peláez-García, A; Redondo, A; Yébenes, L | 1 |
| Kasahara, K; Nishi, K; Okazaki, A | 1 |
| Brady, WE; Christensen, H; Dark, G; Feeney, A; Frumovitz, M; Ganesan, R; Gershenson, DM; Gore, M; Hackshaw, A; Kehoe, S; Ledermann, J; Lord, R; Mackean, M; McCluggage, WG; Montes, A; Penson, RT; Perren, T; Reed, N; Rustin, G; Summers, J; Wilkinson, N; Zaino, R | 1 |
| Baratti, D; Deraco, M; Guaglio, M; Kusamura, S; Nizri, E; Rajendra, VJ; Salcedo-Hernández, RA; Sinukumar, S | 1 |
| Harano, K; Katsumata, N; Sugiyama, T; Takahashi, F; Takakura, S; Takano, M; Terauchi, F; Yamamoto, Y; Yasuda, M | 1 |
| Baggerly, KA; Bottsford-Miller, J; Coleman, RL; Dalton, HJ; Han, HD; Hu, W; Huang, J; Ivan, C; Kang, Y; Lee, JS; Liu, J; Liu, T; Lopez-Berestein, G; Mangala, LS; Miyake, T; Nick, AM; Pecot, CV; Pradeep, S; Previs, RA; Ram, P; Rupaimoole, R; Sehgal, V; Sood, AK; Sun, Y; Tucker, SL; Wu, SY; Zand, B | 1 |
| Barrett, JC; Benzaquen, AO; Cibula, D; Colombo, N; Dougherty, B; Friedlander, M; Hirte, H; Lowe, ES; Mackay, H; Mahner, S; Mathijssen, RH; Oza, AM; Plante, M; Poole, C; Rowbottom, J; Schmalfeldt, B; Sonke, GS; Špaček, J; Vuylsteke, P | 1 |
| Andrade, C; Clark, RM; del Carmen, MG; Esselen, KM; Foley, OW; Hinchcliff, EM; Horowitz, NS; Rauh-Hain, JA; Vargas, RJ; Winograd, D | 1 |
| Mahdi, H; Rizzo, A; Rose, PG | 1 |
| Aziz, AB; Chishti, U | 1 |
| Cozma, A; Muntean, V; Simescu, R; Şimon, I; Togănel, RD; Zolog, A | 1 |
| Hu, T; Liu, H; Shi, Y; Song, SQ; Zhang, GN | 1 |
| Chu, C; Lin, LL; Rubin, S; Xu, MJ | 1 |
| Alexander, H; Banerjee, S; Barton, D; Bodla, S; Georgiou, A; Gore, M; Kaye, S; McLachlan, J; Nobbenhuis, M; Seifert, H | 1 |
| Burger, RA; Cohn, DE; Duska, LR; Java, JJ | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Fernandez, RO; Iniesta, MD; Lu, KH; Malpica, A; Patrono, MG; Ramirez, PT; Salvo, G | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M | 1 |
| Cirik, DA; Karalok, A; Koc, S; Tasci, T; Tulunay, G; Turan, T; Ureyen, I | 1 |
| Acosta, RD; Bruining, DH; Cash, BD; Chandrasekhara, V; Chathadi, KV; DeWitt, JM; Eloubeidi, MA; Faulx, AL; Fonkalsrud, L; Gurudu, SR; Khashab, MA; Kothari, S; Lightdale, JR; Muthusamy, VR; Pasha, SF; Saltzman, JR; Shaukat, A; Wang, A; Yang, J | 1 |
| Adams, N; Barve, M; Bergman, MK; Bognar, E; DeMars, LR; Fine, B; Fleming, EL; Goodman, H; Grosen, E; Hancock, KC; Heffernan, TP; Koon, EC; Kumar, P; Manning, L; Matthews, CM; Nemunaitis, J; Oh, J; Pappen, BO; Senzer, N; Spitz, DL; Wallraven, G; West, L | 1 |
| Chi, DS; Gardner, GJ; Iasonos, A; Kelly, A; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Sonoda, Y; Zhou, Q; Zivanovic, O | 1 |
| Alvarez-Secord, A; Copeland, LJ; Creasman, WT; Hanjani, P; Java, JJ; Kesterson, JP; Morgan, MA; Morris, RT; Rose, PG; Stehman, FB; Warshal, DP | 1 |
| Alvarez Secord, A; Armstrong, DK; Cohn, DE; Copeland, LJ; Garcia-Soto, AE; Java, JJ; Lele, SB; Nieves Neira, W; Pearson, JM; Tewari, KS; Walker, JL | 1 |
| Bottoni, C; Costantini, B; Fagotti, A; Gallotta, V; Gueli Alletti, S; Nardelli, F; Petrillo, M; Quagliozzi, L; Scambia, G; Vizzielli, G | 1 |
| Bell, J; Chan, JK; Fuh, K; Herzog, T; Java, JJ; Kapp, DS; Monk, BJ; Young, R | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Liu, XS; Shao, SL | 1 |
| Brennan, D; Fitzpatrick, P; Furlong, F; Gallagher, M; Maguire, A; Martin, C; McCann, A; McGettigan, P; McGoldrick, A; McGrogan, B; O'Grady, A; O'Leary, J; O'Toole, S; Phelan, S; Prencipe, M; Sheils, O; W Kay, E | 1 |
| Ohara, N | 1 |
| Ino, K; Kajiyama, H; Kikkawa, F; Nawa, A; Shibata, K; Terauchi, M; Umezu, T | 1 |
| Beretta, P; Donadello, N; Franchi, M; Ghezzi, F; Miglierina, M; Zanaboni, F | 1 |
3 review(s) available for paclitaxel and Neoplasms, Cystic, Mucinous, and Serous
| Article | Year |
|---|---|
Serous Carcinoma of the Uterine Cervix, an Extremely Rare Aggressive Entity: A Literature Review.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Risk Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2018 |
Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Incidence; Mutation; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Platinum Compounds; Salpingectomy | 2015 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
9 trial(s) available for paclitaxel and Neoplasms, Cystic, Mucinous, and Serous
| Article | Year |
|---|---|
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian; Bevacizumab; Black or African American; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Ethnicity; Fallopian Tube Neoplasms; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; White People | 2022 |
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Hereditary Breast and Ovarian Cancer Syndrome; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Young Adult | 2022 |
The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol.
Topics: Ablation Techniques; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Ethanol; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pancreatic Cyst; Pancreatic Neoplasms; Pennsylvania; Postoperative Complications; Prospective Studies; Risk Factors; Therapeutic Irrigation; Time Factors; Treatment Outcome | 2017 |
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Follow-Up Studies; Humans; Internationality; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Progression-Free Survival; Quality of Life; Response Evaluation Criteria in Solid Tumors; Survival Rate; Young Adult | 2019 |
Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2014 |
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Time Factors; Treatment Outcome; Young Adult | 2015 |
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Body Mass Index; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Obesity; Ovarian Neoplasms; Paclitaxel; Patient Readmission; Peritoneal Neoplasms; Risk Factors; Time Factors | 2015 |
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carboplatin; Carcinoma, Endometrioid; Cross-Over Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; T-Lymphocytes | 2016 |
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Reoperation; Survival Rate | 2016 |
33 other study(ies) available for paclitaxel and Neoplasms, Cystic, Mucinous, and Serous
| Article | Year |
|---|---|
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy-Related Cognitive Impairment; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fatigue; Female; Humans; Long Term Adverse Effects; Longitudinal Studies; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Sleep Initiation and Maintenance Disorders | 2022 |
MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma.
Topics: Apoptosis; Aurora Kinase B; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Molecular Targeted Therapy; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel | 2020 |
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Time Factors; V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 2021 |
Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; New Zealand; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Prognosis; Retrospective Studies; Treatment Outcome | 2017 |
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
Topics: Adenocarcinoma, Clear Cell; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Turkey | 2017 |
Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Clinical Decision-Making; Cytoreduction Surgical Procedures; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; ROC Curve; Transcriptome | 2018 |
Pseudo-Meigs syndrome caused by cancer of the uterine corpus.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin; Female; Humans; Hysterectomy; Meigs Syndrome; Neoplasms, Cystic, Mucinous, and Serous; Omentum; Paclitaxel; Pleural Effusion; Radiography, Thoracic; Salpingo-oophorectomy; Tomography, X-Ray Computed; Uterine Neoplasms | 2019 |
Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institut
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Length of Stay; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Postoperative Complications; Progression-Free Survival; Retrospective Studies | 2019 |
Notch3 pathway alterations in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Calcium-Binding Proteins; Cell Line, Tumor; Dynamins; Endocytosis; Female; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Kaplan-Meier Estimate; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Cystic, Mucinous, and Serous; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Receptor, Notch3; Receptors, Notch; RNA, Small Interfering; Serrate-Jagged Proteins; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Proportional Hazards Models | 2015 |
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2015 |
Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Endometrioid; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Pakistan; Postoperative Complications; Retrospective Studies; Treatment Outcome | 2015 |
Primary peritoneal serous psammocarcinoma: a case report.
Topics: Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calcinosis; Carboplatin; Chemotherapy, Adjuvant; Colectomy; Cytoreduction Surgical Procedures; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Peritoneal Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Addition of bevacizumab to neoadjuvant chemotherapy for Stage IV ovarian serous adenocarcinoma with multiple lymph node metastases: a case report.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy, Adjuvant; Female; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Treatment Outcome | 2015 |
Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Chemoradiotherapy; Cohort Studies; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pelvic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Survival Rate; Tumor Burden | 2017 |
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Systemic Therapy of Endometrial (Uterine) Cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Progestins; Singapore; Sirolimus; Tamoxifen | 2015 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2016 |
Stage IVB endometrial cancer confined to the abdomen: is chemotherapy superior to radiotherapy?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovariectomy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Salpingectomy | 2016 |
The role of endoscopy in the diagnosis and treatment of cystic pancreatic neoplasms.
Topics: Ablation Techniques; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Cholangiopancreatography, Endoscopic Retrograde; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Ethanol; Humans; Injections, Intralesional; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pancreatic Neoplasms; Solvents | 2016 |
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2016 |
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Time Factors | 2016 |
Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Laparoscopy; Laparotomy; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies | 2016 |
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Survival Rate; Time Factors | 2016 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
[Analysis of prognostic factors of epithelial ovarian carcinoma].
Topics: Adenocarcinoma, Clear Cell; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Young Adult | 2010 |
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium-Binding Proteins; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mad2 Proteins; MicroRNAs; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Paraffin Embedding; Proportional Hazards Models; Repressor Proteins; Retrospective Studies; Risk Assessment; Risk Factors; RNA Interference; Time Factors; Transfection; Treatment Outcome | 2012 |
Ovarian function during chemotherapy with paclitaxel and carboplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovary; Paclitaxel | 2002 |
Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Tubulin | 2008 |
Microlaparoscopy: a new approach to the reassessment of ovarian cancer patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biopsy; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Laparoscopy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Reoperation; Videotape Recording | 2000 |